These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 14976452)
21. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia]. Gao ZW; Liu G; Sheng BW Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675 [TBL] [Abstract][Full Text] [Related]
22. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease. Shafer MW; Mangold L; Partin AW; Haab BB Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876 [TBL] [Abstract][Full Text] [Related]
23. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity. Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428 [TBL] [Abstract][Full Text] [Related]
24. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation. Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818 [TBL] [Abstract][Full Text] [Related]
26. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706 [TBL] [Abstract][Full Text] [Related]
27. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441 [TBL] [Abstract][Full Text] [Related]
28. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496 [TBL] [Abstract][Full Text] [Related]
29. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression. Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756 [TBL] [Abstract][Full Text] [Related]
30. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Tumminello FM; Flandina C; Crescimanno M; Leto G Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092 [TBL] [Abstract][Full Text] [Related]
31. [Behavior of some tumor markers (secretory immunoglobulin A, pregnancy-associated alpha 2-glycoprotein, circulating immune complexes in the serum of patients with breast tumors]. Briese V; Strache RR; Büttner HH; Kunze M; Brock J; Röpcke G Zentralbl Gynakol; 1987; 109(5):265-73. PubMed ID: 3591061 [TBL] [Abstract][Full Text] [Related]
32. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Aydin A; Arsova-Sarafinovska Z; Sayal A; Eken A; Erdem O; Erten K; Ozgök Y; Dimovski A Clin Biochem; 2006 Feb; 39(2):176-9. PubMed ID: 16413012 [TBL] [Abstract][Full Text] [Related]
33. [Circulating immune complexes in the serum of tumor patients]. Alvarez R; García Gómez A; Subiza JL; Domínguez J; Bootello A; Coll J Rev Esp Oncol; 1982; 29(4):727-34. PubMed ID: 6927370 [TBL] [Abstract][Full Text] [Related]
36. Influence of splenectomy on the levels of circulating immune complexes (CIC) in Hodgkin's disease (HD). Nerurkar AV; Advani SH; Gothoskar BP Neoplasma; 1987; 34(1):89-93. PubMed ID: 3561608 [TBL] [Abstract][Full Text] [Related]
37. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074 [TBL] [Abstract][Full Text] [Related]
38. [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?]. Kranjcević K; Marković BB Acta Med Croatica; 2007 Feb; 61(1):45-8. PubMed ID: 17593640 [TBL] [Abstract][Full Text] [Related]
39. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Zhigang Z; Wenlv S Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669 [TBL] [Abstract][Full Text] [Related]
40. Further evidence against preeclampsia as an immune complex disease. Balasch J; Mirapeix E; Borche L; Vives J; González-Merlo J Obstet Gynecol; 1981 Oct; 58(4):435-7. PubMed ID: 6456434 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]